Takeda Pharmaceutical Company Limited (TAK) Morgan Stanley 23rd Annual Global Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT
Company Participants
Milano Furuta – CFO & Director
Conference Call Participants
Shinichiro Muraoka – Morgan Stanley, Research Division
Presentation
Shinichiro Muraoka
Equity Analyst
Okay. So let’s start the session with Takeda. My name is Shinichiro Muraoka, covering Japanese pharma. And before starting this, for important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So yes, let’s get started with Takeda. The speaker is CFO, Mr. Milano Furuta. Thank you for joining us.
Milano Furuta
CFO & Director
Thank you for having me here.
Question-and-Answer Session
Shinichiro Muraoka
Morgan Stanley, Research Division
Thank you. So yes, you have many pipelines from the last year’s R&D Day, investors awareness, interest on your pipeline has evolved significantly in the last 1 year. And today — yesterday today, you have a new update of oveporexton narcolepsy Type 1 results. So I’d like to start with about oveporexton. First of all, so what’s your appealing point of the molecule in the Phase III study?
Milano Furuta
CFO & Director
Thank you, Muraoka-san. Hello, everyone. My name is Milano, CFO of Takeda. Just before we start last question, specifically, Muraoka-san, you mentioned a very important point, Takeda is now bringing 6 late-stage assets and which we project peak sales combined $10 billion to $20 billion. And our total revenue of Takeda is now a bit more than $30 billion. You can see the magnitude of the potential of these late-stage assets. We have 6 late-stage assets.
And then this year, 2025, is quite exciting year for us because we have the 3 readouts of — among those 6. So one is rusfertide, the molecule for the polycythemia
